Pacira BioSciences, Inc.: updates and filings

PCRXNASDAQHealthcare · Pharmaceutical Preparations

Price

$36.48

November 16, 2026Market cap $1.5B

What Ploutos Investor adds for Pacira BioSciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 76 daysAround Feb 4, 2027 · for Q4 2026

last Aug 4, 2026next Feb 4, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 26, 2026 latest annualNov 5, 2026 latest quarterly
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Filing
    FormS-8 POS
  • Nov 17, 2026Material agreement entered, material agreement ended, acquisition or disposal of assets, event accelerating an obligation, delisting notice, change to shareholders' rights, change in control, officer or director change, amended articles or bylaws, Regulation FD disclosure
    Form8-K
  • Nov 17, 2026Filing (amendment)
    FormSC 14D9/A
  • Nov 17, 2026Filing (amendment)
    FormSC TO-T/A
  • Nov 17, 2026One of its securities removed from an exchange (usually a matured note)
    Form25-NSE
  • Nov 12, 2026Regulation FD disclosure
    Form8-K
  • Nov 12, 2026Filing (amendment)
    FormSC TO-T/A
  • Nov 12, 2026Filing (amendment)
    FormSC 14D9/A
  • Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 5, 2026Regulation FD disclosure
    Form8-K
  • Nov 3, 2026Filing (amendment)
    FormSC 14D9/A
  • Oct 30, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 30, 2026Filing
    FormSC 14D9

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 16, 2007.

The full analysis

What do Pacira BioSciences's filings show?

The filings are where every one of Pacira BioSciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.